A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

BACKGROUND: Cabozantinib is an oral MET/VEGFR2 inhibitor. A recent phase II study of cabozantinib (100mg daily) demonstrated improved bone scans in subjects with metastatic castration-resistant prostate cancer (mCRPC), but adverse events (AEs) caused frequent dose reductions. This study was designed...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, Richard J., Saylor, Philip J., Michaelson, M. Dror, Rothenberg, S. Michael, Smas, Malgorzata E., Miyamoto, David T., Gurski, Carol A., Xie, Wanling, Maheswaran, Shyamala, Haber, Daniel A., Goldin, Jonathan G., Smith, Matthew R.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2013
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3684567/
https://ncbi.nlm.nih.gov/pubmed/23553848
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-0319
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak